SCHEMBL4594069

SCHEMBL4594069

CC(=O)C(=O)OCN1CCN(CCO[N+](=O)[O-])CC1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
HRH2 P25021 2/20 0.33
HRH1 P35367 2/20 0.33
KDM4E B2RXH2 4/20 0.32
ALDH1A1 P00352 3/20 0.32
KCNJ1 P48048 1/20 0.32
KCNH2 Q12809 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
DRD3 P35462 1/20 0.31
SLC29A1 Q99808 1/20 0.31
PTGS2 P35354 1/20 0.30
SLC18A3 Q16572 1/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
HTT P42858 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4594907 0.92 HRH2 (0.37) HRH2HRH1KDM4EALDH1A1KCNH2
SCHEMBL4594584 0.91 MMP2 (0.35) MMP2MMP9HRH2HRH1KDM4E
SCHEMBL4593090 0.88 SLC29A1 (0.33) HRH2HRH1KDM4EALDH1A1KCNJ1
SCHEMBL4588380 0.88
SCHEMBL4594002 0.87 HRH2 (0.40) HRH2HRH1KDM4EALDH1A1KCNH2
SCHEMBL4593888 0.84 HRH2 (0.37) HRH2HRH1KDM4EALDH1A1KCNH2
SCHEMBL4593562 0.83 HRH2 (0.37) HRH2HRH1KDM4EALDH1A1KCNH2
SCHEMBL4594022 0.82 HRH2 (0.38) HRH2HRH1KDM4EALDH1A1KCNH2
SCHEMBL14607652 0.74 MMP2 (0.39) MMP2MMP9KDM4EALDH1A1TDP1
SCHEMBL4585982 0.73 GSR (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US claimed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP disclosed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP disclosed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 MMP2 2437/4885MMP9 1629/4885HRH2 4231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.